Rubraca should be used with caution in certain patient populations due to potential adverse effects.

Precautions for Using Rubraca

Before prescribing Rubraca, healthcare providers must assess the patient's renal function, as dose adjustments may be necessary for those with moderate to severe renal impairment. The drug should be used with caution in patients with a history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), as these conditions may worsen. Additionally, monitoring for hematologic toxicities, including anemia, neutropenia, and thrombocytopenia, is crucial during treatment. Rubraca's use during pregnancy and lactation is not recommended due to potential risks to the fetus or infant, though specific recommendations are not provided in the document.